StockNews.com began coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a research report report published on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
22nd Century Group Stock Down 9.8 %
Shares of NASDAQ XXII opened at $0.23 on Thursday. The stock has a market cap of $1.89 million, a PE ratio of 0.00 and a beta of 1.41. 22nd Century Group has a 52-week low of $0.22 and a 52-week high of $16.00. The business has a 50-day moving average price of $0.48 and a 200 day moving average price of $4.07.
22nd Century Group (NASDAQ:XXII – Get Free Report) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. 22nd Century Group had a negative net margin of 275.12% and a negative return on equity of 380.39%. The firm had revenue of $7.95 million during the quarter.
Institutional Trading of 22nd Century Group
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Featured Articles
- Five stocks we like better than 22nd Century Group
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Top Stocks Investing in 5G Technology
- MarketBeat Week in Review – 9/23 – 9/27
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.